Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Free Cash Flow: 2021-2025

Historic Free Cash Flow for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$35.3 million.

  • Prime Medicine's Free Cash Flow fell 29.78% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.1 million, marking a year-over-year increase of 39.52%. This contributed to the annual value of -$130.2 million for FY2024, which is 25.25% up from last year.
  • As of Q3 2025, Prime Medicine's Free Cash Flow stood at -$35.3 million, which was up 17.91% from -$43.0 million recorded in Q2 2025.
  • Prime Medicine's 5-year Free Cash Flow high stood at $14.5 million for Q4 2024, and its period low was -$70.0 million during Q1 2024.
  • In the last 3 years, Prime Medicine's Free Cash Flow had a median value of -$43.0 million in 2025 and averaged -$39.4 million.
  • As far as peak fluctuations go, Prime Medicine's Free Cash Flow tumbled by 161.82% in 2022, and later surged by 131.63% in 2024.
  • Over the past 5 years, Prime Medicine's Free Cash Flow (Quarterly) stood at -$13.6 million in 2021, then tumbled by 161.82% to -$35.5 million in 2022, then decreased by 28.65% to -$45.7 million in 2023, then surged by 131.63% to $14.5 million in 2024, then fell by 29.78% to -$35.3 million in 2025.
  • Its Free Cash Flow was -$35.3 million in Q3 2025, compared to -$43.0 million in Q2 2025 and -$51.3 million in Q1 2025.